Expanding access to perioperative and repurposed cancer drug trials
Official title: Expanding access to perioperative and repurposed drug trials in melanoma and other solid tumors
Funded at Emory University · NIH-11416796 · Data updated 2026-11-12
This grant helps Emory broaden participation in nodal cancer trials and repurposed-drug studies to improve care for people with melanoma and other solid tumors.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 10, 2025 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $83,925 |
| NIH project number | 5R50CA292121-02 |
| Project ID | NIH-11416796 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with melanoma or other solid tumors who are eligible for NCI-sponsored and repurposed-drug trials through Emory/Winsip programs.
✕Less likely to help
Patients not eligible for available trials or not seeking trial participation may not experience direct benefit.
What this research studies
The grant supports increasing the university’s involvement in NCI-sponsored cancer trials, with a focus on perioperative settings and repurposed drugs. It highlights leadership from Dr. Michael Lowe and a track record of enrolling patients in ECOG-ACRIN and NCTN trials. The effort aims to connect patients with cutting-edge trials through the Melanoma Program and the Morningside Center for Innovative and Affordable Medicine. Participants could benefit from earlier access to promising therapies within established cooperative groups.
Why it matters
Potential benefit: Broader access to innovative trial options could lead to new treatment opportunities for patients with melanoma and other solid tumors.
How similar studies have gone: Emory has a history of enrolling patients in multiple NCI cooperative group trials, indicating a proven pathway for trial access and accrual.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Lowe, Michael — Emory University
- Study coordinator: Lowe, Michael
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors
A program uses mouse tumor models to identify promising drug candidates for children with sarcoma and other solid tumors.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.